Genetic polymorphisms in human drug-metabolizing enzymes: Potential uses of reverse genetics to identify genes of toxicological relevance

Critical Reviews in Toxicology

Volumn 27, Issue 2, 1997, Pages 199-222

  Puga, Alvaro ^a   Nebert, Daniel W ^a   McKinnon, Ross A ^a,b   Menon, Anil G ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Cytochromes P450; Environmental genetics; Genetic variability; Risk assessment

Indexed keywords

DRUG METABOLIZING ENZYME;

CANCER SUSCEPTIBILITY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MUTATION; PHENOTYPE; REVIEW; RISK ASSESSMENT; TOXICOLOGY;

EID: 0030935831     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408449709021619     Document Type: Review

References (243)

1. Kalow, W., Pharmacogenetics: its biological roots and the medical challenge, Clin. Pharmacol. Ther., 54, 235, 1993.
2. Kalow, W., Life of a pharmacologist or the rich life of a poor metabolizer (invited autobiographical account), Pharmacol. Toxicol., 76, 221, 1995.
3. Motulsky, A. G., Pharmacogenetics and ecogenetics in 1991, Pharmacogenetics, 1, 2, 1991.
4. Caporaso, N. E. and Goldstein, A., Cancer genes: single and susceptibility: exposing the difference, Pharmacogenetics, 5, 59, 1995.
5. Nebert, D. W. and Gonzalez, F. J., P450 genes. Structure, evolution and regulation, Annu. Rev. Biochem., 56, 945, 1987.
6. Nebert, D. W. and McKinnon, R.A., Cytochrome P450: evolution and functional diversity, Prog. Liver Dis., 12, 63, 1994.
7. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., et al., The P450 superfamily: update on new sequences, gane mapping, accession numbers, early trivial names of enzymes, and nomenclature, DNA Cell Biol., 12, 1, 1993.
8. Nebert, D. W., Nelson, D. R., Coon, M. J., Estabrook, R. W., Feyereisen, R., Fujii-Kuriyama, Y., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., et al., The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature, DNA Cell Biol., 10, 1, 1991.
9. Lawton, M. P., Cashman, J. R., Cresteil, T., Dolphin, C. T., Elfarra, A. A., Hines, R. N., Hodgson, E., Kimura, T., Ozols, J., Phillips, I. R., et al., Mammalian flavin-containing monooxygenase gene families based on amino acid sequence identities, Arch. Biochem. Biophys., 308, 254, 1994.
10. Burchell, B., Nebert, D. W., Nelson, D. R., Bock, K. W., Iyanagi, T., Jansen, P. L. M., Lancet, D., Mulder, G. J., Chowdhury, J. R., Siest, G., et al., The UDP-glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence, DNA Cell Biol., 10, 487, 1991.
11. Nebert, D. W., Identification of genetic differences in drug metabolism: prediction of individual risk of toxicity or cancer, Hepatology, 14, 398, 1991.
12. Nebert, D. W., Role of genetics and drug metabolism in human cancer risk, Mutat. Res., 247, 267, 1991.
13. Nebert, D. W., The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects, Crit. Rev. Toxicol., 20, 153, 1989.
14. Nebert, D. W., Petersen, D. D., and Puga, A., Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin, Pharmacogenetics, 1, 68, 1991.
15. Gonzalez, F. J., The molecular biology of cytochrome P450s, Pharmacol. Rev., 40, 243, 1988.
16. Greenlee, W. F. and Neal, R. A., The Ah receptor: a biochemical and biological perspective, inThe Receptors, Vol. 2, Conn, P.M., Ed., New York, Academic Press, 1985, 89.
17. Burbach, K. M., Poland, A., and Bradfield, C. A., Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor, Proc. Natl. Acad. Sci. U.S.A., 89, 8185, 1992.
18. Ema, M., Sogawa, K., Watanabe, N., Chujoh, Y., Matsushita, N., Gotoh, O., Funae, Y., and Fujii-Kuriyama, Y., cDNA cloning and structure of mouse putative Ah receptor, Biochem. Biophys. Res. Commun., 184, 246, 1992.
19. Hankinson, O., Research on the aryl hydrocarbon (dioxin) receptor is primed to take off, Arch. Biochem. Biophys., 300, 1, 1993.
20. Swanson, H. I. and Bradfield, C. A., The AH-receptor: genetics, structure and function, Pharmacogenetics, 3, 213, 1993.
21. Landers, J. P. and Bunce, N. J., The Ah receptor and the mechanism of dioxin toxicity, Biochem. J., 276, 273, 1991.
22. Nebert, D. W., Puga, A., and Vasiliou, V., Role of the Ah receptor and dioxin inducible [Ah] gene battery in toxicity, cancer, and signal transduction, Ann. N. Y. Acad. Sci., 685, 624, 1993.
23. Whitlock, J. P., Jr., Genetic and molecular aspects of 2,3,7,8-tetrachlorodibenzo-p-dioxin action, Annu. Rev. Pharmacol. Toxicol., 30, 251, 1991.
24. 1-450 formation by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice genetically "non-responsive" to other aromatic hydrocarbons, J. Biol. Chem., 249, 5599, 1974.
25. Poland, A., Palen, D., and Glover, E., Analysis of the four alleles of the murine aryl hydrocarbon receptor, Mol. Pharmacol., 46, 915, 1994.
26. Ema, M., Ohe, N., Suzuki, M., Mimura, J., Sogawa, K., Ikawa, S., and Fujii-Kuriyama, Y., Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors, J. Biol. Chem., 269, 27337, 1994.
27. Chang, C.-Y., Smith, D. R., Prasad, V. S., Sidman, C. L., Nebert, D. W., and Puga, A., Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice, Pharmacogenetics, 3, 312, 1993.
28. 3H]tetrachlorodibenzo-p-dioxin, Cancer Res., 46, 3739, 1986.
29. Vanden Heuvel, J. P., Clark, G. C., Thompson, C. L., McCoy, Z., Miller, C. R., Lucier, G. W., and Bell, D. A., CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes, Carcinogenesis, 14, 2003, 1993.
30. Kellerman, G., Shaw, C. R., and Luyten-Kellerman, M., Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma, N. Engl. J. Med., 289, 934, 1973.
31. Fingerhut, M. A., Halperin, W. E., Marlow, D. A., Piacitelli, L. A., Honchar, P. A., Sweeney, M. H., Greife, A. L., Dill, P. A., Steenland, K., and Suruda, A. J., Cancer mortality in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin, N. Engl. J. Med., 324, 212, 1991.
32. Manz, A., Berger, J., Dwyer, J. H., Flesch-Janys, D., Nagel, S., and Waltsgott, H., Cancer mortality among workers in chemical plant contaminated with dioxin, Lancet, 338, 959, 1991.
33. Bertazzi, P. A., Long-term effects of chemical disasters. Lessons and results from Seveso, Sci. Total Environ., 106, 5, 1991.
34. Kouri, R. E., McKinney, C. E., Slomiany, D. J., Snodgrass, D. R., Wray, N. P., and McLemore, T. L., Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes, Cancer Res., 42, 5030, 1982.
35. Coombs, M. L., Mason, W. A., Muijsson, I. E., Cantrell, E. T., Anderson, D. E., and Busbee, D. L., Aryl hydrocarbon hydroxylase and testosterone 16α-hydroxylase in cultured human lymphocytes, Biochem. Genet., 14, 671, 1976.
36. Guirgis, H. A., Lynch, H. T., Mate, T., Harris, R. E., Wells, I., Caha, L., Anderson, J., Maloney, K., and Rankin, L., Aryl hydrocarbon hydroxylase activity in lymphocytes from lung cancer patients and normal controls, Oncology, 33, 105, 1976.
37. Emery, A. E. H., Danford, N., Anand, R., Duncam, W., and Paton, L., Aryl hydrocarbon hydroxylase inducibility in patients with cancer, Lancet, 1, 470, 1978.
38. Körsgaard, R. and Trell, E., Aryl hydrocarbon hydroxylase and bronchogenic carcinomas associated with smoking, Lancet, 1, 1103, 1978.
39. Arnott, M. S., Yamauchi, T., and Johnston, D. A., Aryl hydrocarbon hydroxylase in normal and cancer populations, in Carcinogens: Identification and Mechanisms of Action, Griffin, A.C. and Shaw, C.R, Eds., Raven Press, New York, 1979, 145.
40. Gahmberg, C. G., Sekki, A., Kosunen, T. U., Holsti, L. R., and Makela, O., Induction of aryl hydrocarbon hydroxylase activity and pulmonary carcinoma, Int. J. Cancer, 23, 302, 1979.
41. McLemore, T. L., Martin, R. R., Springer, R. R., Wray, N., Cantrell, E. T., and Busbee, D. L., Aryl hydrocarbon hydroxylase acticity in pulmonary alveolar macrophages and lymphocytes from lung cancer and noncancer patients, Biochem. Genet., 17, 795, 1979.
42. Trell, E., Körsgaard, R., Hood, B., Kitzing, P., Norden, G., and Simonsson, B. G., Aryl hydrocarbon hydroxylase inducibility and laryngeal carcinomas, Lancet, 2, 140, 1976.
43. Trell, E. and Körsgaard, R., Smoking and oral carcinoma, Lancet, 1, 671, 1978.
44. Trell, E., Körsgaard, R., Kitzing, P., Lundgren, K., and Mattiasson, I., Aryl hydrocarbon inducibility and carcinoma of oral cavity, Lancet, 1, 109, 1978.
45. Shields, P. G., Sugimura, H., Caporaso, N. E., Petruzzelli, S. F., Bowman, E. D., Trump, B. F., Weston, A., and Harris, C., Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 RFLP, Environ. Health Perspect., 98, 191, 1992.
46. Trell, E., Oldbring, J., Körsgaard, R., and Mattiasson, I., Aryl hydrocarbon hydroxylase inducibility in carcinoma of renal pelvis and ureter, Lancet, 2, 612, 1977.
47. Trell, E., Oldbring, J., Körsgaard, R., Hellsten, S., Mattiasson, I., and Telhammar, E., Aryl hydrocarbon hydroxylase inducibility and carcinoma of the urinary bladder, IRCS J. Med. Sci., 6, 138, 1978.
48. Gurtoo, H. L., Minowada, J., Paigen, B., Parker, N. B., and Hayner, N. T., Factors influencing the measurement and the reproducibility of aryl hydrocarbon hydroxylase activity in cultured human lymphocytes, J. Nat. Cancer Inst., 59, 787, 1977.
49. Jett, J. R., Moses, H. L., Branum, E. L., Taylor, W. F., and Fontana, R. S., Benzo[a]pyrene metabolism and blast formation in peripheral blood mononuclear cells from smoking and non-smoking populations and lung cancer patients, Cancer, 41, 192, 1978.
50. Lieberman, J., Aryl hydrocarbon hydroxylase in bronchogenic carcinoma, N. Engl. J. Med., 298, 686, 1978.
51. Paigen, B., Gurtoo, H. L., Minowada, J., Houten, L., Vincent, R., Paigen, K., Parker, N. B., Ward, E., and Hayner, N. T., Questionable relation of aryl hydrocarbon hydroxylase to lung cancer risk, N. Engl. J. Med., 297, 346, 1977.
52. Ward, E., Paigen, B., Steenland, K., Vincent, R., Minowada, J., Gurtoo, H. L., Sartori, P., and Havens, M.B., Aryl hydrocarbon hydroxylase in persons with lung or laryngeal cancer, Int. J. Cancer, 23, 312, 1979.
53. Landi, M. T., Bertazzi, P. A., Shields, P. G., Clark, G., Lucier, G. W., Garte, S. J., Cosma, G., and Caporaso, N. E., Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans, Pharmacogenetics, 4, 242, 1994.
54. Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., and Bradfield, C. A., Cloning and expression of a human Ah receptor cDNA, Mol. Pharmacol., 44, 911, 1993.
55. Takahashi, Y., Itoh, S., Shimojima, T., and Kamataki, T., Characterization of Ah receptor promoter in human liver cell line, HepG2, Pharmacogenetics, 4, 219, 1994.
56. Fujii-Kuriyama, Y., Ema, M., Matsushita, N., and Sogawa, K., Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene, Pharmacogenetics, 5, S149, 1995.
57. Fernandez-Salguero, P., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S. T., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M., and Gonzalez, F. J., Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor, Science, 268, 722, 1995.
58. 2-450 cDNA nucleotide and amino acid sequences, J. Biol. Chem., 259, 10705, 1984.
59. 1450 cDNA probe, Cytogen. Cell Genet., 46, 574, 1987.
60. Kawajiri, K., Nakachi, K., Imai, K., Yoshii, A., Shinoda, N., and Watanabe, J., Identification of genetically high risk individuals to lung cancer by polymorphisms of the cytochrome P450IA1 gene, FEBS Lett., 263, 131, 1990.
61. Hayashi, S.-I., Watanabe, J., Nakachi, K., and Kawajiri, K., Genetic linkage of lung cancer-associates Msp I polymorphisms with amino acid replacement in the heme-binding region of the human cytochrome P450IA1 gene, J. Biochem. (Tokyo), 110, 407, 1991.
62. Hayashi, S.-I., Watanabe, J., Nakachi, K., and Kawajiri, K., PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene, Nucleic Acids Res., 19, 4797, 1991.
63. Hayashi, S., Watanabe, J., and Kawajiri, K., High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes, Jpn. J. Cancer Res., 83, 866, 1992.
64. Nakachi, K., Imai, K., Hayashi, S., and Kawajiri, K., Polymorphisms of the CYP1A1 and glutathione S-transterase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population, Cancer Res., 53, 2994, 1993.
65. 1450) gene: lack of assodation between the Mxp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population, Pharmacogenetics, 1, 20, 1991.
66. Shields, P. G., Bowman, E. D., Harrington, A. M., Doan, V. T., and Weston, A., Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes, Cancer Res., 53, 3486, 1993.
67. Hirvonen, A., Husgafvel-Pursiainen, K., Karjalainen, A., Anttila, S., and Vainio, H., Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population, Cancer Epidemiol. Biomark. Prev., 1, 485, 1992.
68. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A., Sorsa, M., and Vainio, H., Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer, Pharmacogenetics, 2, 259, 1992.
69. Wedlund, P. J., Kimura, S., Gonzalez, F. J., and Nebert, D. W., 1462V mutation in the human CYP1A1 gene: lack of correlation with either the Msp I 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent, Pharmacogenetics, 4, 21, 1994.
70. Crofts, F., Cosma, G. N., Currie, D., Taioli, E., Toniolo, P., and Garte, S. J., A novel CYP1A1 gene polymorphism in African-Americans, Carcinogenesis, 14, 1729, 1993.
71. Taioli, E., Crofts, F., Trachman, J., Demopoulos, R., Toniolo, P., and Garte, S. J., A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung, Cancer Res., 55, 472, 1995.
72. Kelsey, K. T., Wiencke, J. K., and Spitz, M. R., A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African-Americans, Carcinogenesis, 15, 1121, 1994.
73. London, S. J., Daly, A. K., Fairbrother, K., Holmes, C., Carpenter, C. L., Navidi, W. C., and Idle, J. R., Lung cancer risk in African-Americans in relation to a races-pecific CYP1A1 polymorphism, Cancer Res., 55, 6035, 1995.
74. Taioli, E., Trachman, J., Chen, X., Toniolo, P., and Garte, S. J., A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women, Cancer Res., 55, 3757, 1995.
75. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R., and Smith, R. L., Polymorphic hydroxylation of debrisoquine in man, Lancet, 2, 584, 1977.
76. Gonzalez, F. J. and Meyer, U. A., Molecular genetics of the debrisoquine-sparteine polymorphism, Clin. Pharmacol. Ther., 50, 233, 1991.
77. Johansson, I., Oscarson, M., Yue, Q.-Y., Bertilsson, L., Sjöqvist, F., and Ingelman-Sundberg, M., Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation, Mol. Pharmacol., 46, 452, 1994.
78. Bertilsson, L., Lou, Y. Q., Dy, Y. L., Liu, Y., Kuang, T. Y., Liao, X. M., Wang, K. Y., Reviriego, J., Iselius, L., and Sjöqvist, F., Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin, Clin. Pharmacol. Ther., 51, 388, 1992.
79. Mannervik, B., Awasthi, Y. C., Board, P. G., Hayes, J. D., Di Ilio, C., Ketterer, B., Listowsky, I., Morgenstern, R., Muramatsu, M., Pearson, W. R., et al., Nomeclature for human glutathione transferases, Biochem. J., 282, 305, 1992.
80. Buchert, E. T. and Woosley, R. L., Clinical implications of variable antiarrhythmic drug metabolism, Pharmacogenetics, 2, 2, 1992.
81. Nebert, D. W., Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk, Cancer Cells, 3, 93, 1991.
82. Gonzalez, F. J. and Idle, J. R., Pharmacogenetic phenotyping and genotyping: present status and future potential, Clin. Pharmacokinet., 26, 59, 1994.
83. Caporaso, N., DeBaun, M. R., and Rothman, N., Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association, Pharmacogenetics, 5, S129, 1995.
84. Steen, V., Andreassen, O. A., Daly, A. K., Tefre, T., Borresen, A.-L., Idle, J. R., and Gulbrandsen, A.-K., Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR methodology, Pharmacogenetics, 5, 215, 1995.
85. Meyer, U. A., Pharmacogenetics: the slow, the rapid and the ultrarapid, Proc. Natl. Acad. Sci. U.S.A., 91, 1983, 1994.
86. Barbeau, A. E., Cloutier, T., Roy, M., Plasse, L., Paris, S., and Poirier, J., Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine, Lancet, 2, 1213, 1985.
87. Poirier, J., Roy, M., Campanella, G., Cloutier, T., and Paris, S., Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs, Lancet, 2, 386, 1987.
88. Steventon, G. B., Heathfield, M. T. E., Waring, R. H., and Williams, A. C., Xenobiotic metabolism in Parkinson's disease, Neurology, 39, 883, 1989.
89. Steiger, M. J., Lledo, P., Quinn, N. P., Marsden, C. D., Turner, P., and Jenner, P. G., Debrisoquine hydroxylation in Parkinson's disease, Acta Neurol. Scand., 86, 159, 1992.
90. Gudjonsson, O., Sanz, E., Alvan, G., Aquilonius, S.-M., and Reviriego, J., Poor hydroxylator phenotypes of debrisoquine are not overrepresented in a group of patients with Parkinson's disease, Br. J. Clin. Pharmacol., 30, 301, 1990.
91. Kallio, J., Martilli, R. J., Rinne, U. K., Sonninen, V., and Syvälathi, E., Debrisoquine oxidation in Parkinson's disease, Acta Neurol. Scand., 83, 194, 1991.
92. Kondo, I. and Kanazawa, I., Debrisoquine hydroxylase and Parkinson's disease, Adv. Neurol., 60, 338, 1993.
93. Armstrong, M., Daly, A. K., Cholerton, S., Bateman, D. N., and Idle, J. R., Mutant debrisoquine hydroxylation genes in Parkinson's disease, Lancet, 339, 1017, 1992.
94. Smith, C. A. D., Gough, A. C., Leigh, P. N., Summers, B. A., Harding, A. E., Maranganore, D. M., Sturman, S. G., Schapira, A. H. V., Williams, A. C., Spurr, N. K., et al., Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease, Lancet, 339, 1375, 1992.
95. Tyndale, R. F., Sunahara, R., Inaba, T., Kalow, W., Gonzalez, F. J., and Niznik, H. B., Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6, Mol. Pharmacol., 40, 63, 1991.
96. Sindrup, S. H., Poulsen, L., Brosen, K., Arendt-Nielsen, L., and Gram, L. F., Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?, Pain, 53, 335, 1993.
97. Sindrup, S. H. and Brosen, K., The pharmacogenetics of codeine hypoalgesia, Pharmacogenetics, 5, 335, 1995.
98. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R., Metabolic oxidation phenotypes are markers for susceptibility to lung cancer, Nature, (London), 312, 169, 1984.
99. Roots, I., Drakoulis, N., and Brockmoller, J., Polymorphic enzymes and cancer risk: concepts, methodology and data review, in Pharmacogenetics of Drug Metabolism, Kalow, W., Ed., Pergamon Press, New York, 1992, 815.
100. Ingelman-Sundberg, M., Johansson, I., Persson, I., Yue, Q.-Y., Dahl, M. L., Bertilsson, L., and Sjöqvist, F., Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer, Pharmacogenetics, 2, 264, 1992.
101. Caporaso, N. E., Tucker, M. A., Hoover, R. N., Hayes, R. B., Pickle, L. W., Issaq, H. J., Muschik, G. M., Green-Gallo, L., Buivys, D., Aisner, S., et al., Lung cancer and the debrisoquine metabolic phenotype, J. Natl. Cancer Inst., 82, 1264, 1990.
102. Cholerton, S., Arpanahi, A., McCracken, N., Boustead, C., Taber, H., Johnstone, E., Leathart, J., Daly, A. K., and Idle, J. R., Poor metabolisers of nicotine and CYP2D6 polymorphism, Lancet, 343, 62, 1994.
103. Koop, D. R., Oxidative and reductive metabolism by cytochrome P450 2E1, FASEB J., 6, 724, 1992.
104. Snawder, J. E., Roe, A. L., Benson, R. W., Casciano, D. A., and Roberts, D. W., Cytochrome P450-dependent metabolism of acetaminophen in four human transgenic lymphoblastoid cell lines, Pharmacogenetics, 4, 43, 1994.
105. Guengerich, F. P., Kim, D.-H., and Iwasaki, M., Role of human P-450 IIE1 in the oxidation of many low molecular weight cancer suspects, Chem. Res. Toxicol., 4, 168, 1991.
106. Guengerich, F. P., Polymorphism of cytochrome P-450 in humans, Trends Pharmacol. Sci., 10, 107, 1989.
107. Daly, A. K., Cholerton, S., Armstrong, M., and Idle, J. R., Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility, Environ. Health Perspect., 102 (Suppl. 9), 55, 1994.
108. McBride, O. W., Umeno, M., Gelboin, H. V., and Gonzalez, F. J., Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E), Nucleic Acids Res., 15, 10071, 1987.
109. Uematsu, F., Kikuchi, H., Ohmachi, T., Sagami, I., Motomiya, M., Kamataki, T., Komori, M., and Watanabe, M., Two common RFLPs of the CYP2E gene, Nucleic Acids Res., 19, 2803, 1991.
110. Hayashi, S., Watanabe, J., and Kawajiri, K., Ge netic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene, J. Biochem., 110, 559, 1991.
111. Watanabe, J., Hayashi, S.-I., Nakachi, K., Imai, K., Suda, Y., Sekine, T., and Kawajiri, K., Pst I and Rsa 1 RFLP in complete linkage disequilibrium at the CYP2E1 gene, Nucleic Acids Res., 18, 7194, 1990.
112. Stephens, E. A., Taylor, J. A., Kaplan, N., Yang, C.-H., Hsieh, L. L., Lucier, G. W., and Bell, D. A., Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese, Pharmacogenetics, 4, 185, 1994.
113. Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Sagami, I., Ohmachi, T., Wakui, A., Kanamaru, R., and Watanabe, M., Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer, Jpn. J. Cancer Res., 82, 254, 1991.
114. Persson, I., Johansson, I., Bergung, H., Dahl, M.-L., Seidegard, J., Rylander, R., Rannug, A., Högberg, J., and Ingelman-Sundberg, M., Genetic polymorphism of cytochrome P4502E1 in a Swedish population: relationship to lung cancer, FEBS Lett., 319, 207, 1993.
115. Uematsu, F., Ikawa, S., Kikuchi, H., Sagami, I., Kanamaru, R., Abe, T., Satoh, K., Motomiya, M., and Watanabe, M., Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure, Pharmacogenetics, 4, 58, 1994.
116. Tsutsumi, M., Lasker, J. M., Shimizu, M., Rosman, A. S., and Lieber, C. S., The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver, Hepatology, 10, 437, 1989.
117. Wrighton, S. A., Thomas, P. E., Molowa, D. T., Haniu, M., Shively, J. F., Maines, S. L., Watkins, P. B., Parker, G., Mendez-Picon, G., Levin, W., et al., Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase, Biochemistry, 25, 6371, 1986.
118. Takahashi, T., Lasker, J. M., Rosman, A. S., and Lieber, C. S., Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase of encoding mRNA, Hepatology, 17, 236, 1992.
119. Peterson, F. J., Holloway, D. E., Erickson, R. R., Duquette, P. H., McClain, C. J., and Holtzman, J. L., Ethanol induction of acetaminophen toxicity and metabolism, Life Sci., 37, 1705, 1980.
120. Lucas, D., Ménez, C., Girre, C., Berthou, F., Bodénez, P., Joannet, I., Hispard, E., Bardou, L.-G., and Ménez, J. F., Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects, Pharmacogenetics, 5, 298, 1995.
121. Ayesh, R., Mitchell, S. C., and Smith, R. L., Body malodour syndromes, Lancet, 345, 1308, 1995.
122. Ayesh, R., Mitchell, S. C., Zhang, A., and Smith, R. L., The fish odour syndrome: biochemical, familial, and clinical aspects (see comments), BMJ, 307, 655, 1993.
123. Dolphin, C., Shephard, E. A., Povey, S., Palmer, C. N., Ziegler, D. M., Ayesh, R., Smith, R. L., and Phillips, I. R., Cloning, primary sequence, and chromosomal mapping of a human flavin-containing monooxygenase (FMO1), J. Biol. Chem., 266, 12379, 1991.
124. Grant, D. M., Molecular genetics of the N-acetyltransferases, Pharmacogenetics, 3, 45, 1993.
125. Lawton, M. P. and Philpot, R. M., Molecular genetics of the flavin-dependent monooxygenases, Pharmacogenetics, 3, 40, 1993.
126. Hines, R. N., Cashman, J. R., Philpot, R. M., Williams, D. E., and Ziegler, D. M., The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression, Toxicol. Appl. Pharmacol., 125, 1, 1994.
127. Seidegard, J. and DePierre, J., Microsomal epoxide hydrolase properties, regulation and function, Biochim. Biophys. Acta, 695, 251, 1983.
128. Farin, F. M. and Omiecinski, C. J., Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue, J. Toxicol. Environ. Health, 40, 317, 1993.
129. Farin, F. M., Pohlman, T. H., and Omiecinski, C. J., Expression of cytochrome P450s and microsomal epoxide hydrolase in primary cultures of human umbilical vein endothelial cells, Toxicol. Appl. Pharmacol., 124, 1, 1994.
130. Heckbert, S. R., Weiss, N. S., Hornung, S. K., Eaton, D. L., and Motulsky, A. G., Glutathione-S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers, J. Natl. Cancer Inst., 84, 414, 1992.
131. Gaedigk, A., Spielberg, S. P., and Grant, D. M., Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions, Pharmacogenetics, 4, 142, 1994.
132. Hassett, C., Aicher, L., Sidhu, J. S., and Omiecinski, C. J., Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants, Hum. Mol. Genet., 3, 421, 1994.
133. 1, Proc. Natl. Acad. Sci. U.S.A., 92, 2384, 1995.
134. Lind, C., Cadenas, E., Hochstein, P., and Ernster, L., DT-Diaphorase: purification, properties and function, Methods Enzymol., 186, 287, 1990.
135. Jaiswal, A. K., Human NAD(P)H: quinone oxydoreductase (NQO1) gene structure and induction by dioxin, Biochemistry, 30, 10647, 1991.
136. Jaiswal, A. K., McBride, O. W., Adesnik, M., and Nebert, D. W., Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase, J. Biol. Chem., 263, 13572, 1988.
137. Traver, R. D., Tetsuro, H., Danenberg, K. D., Stadlbauer, T. H. W., Danenberg, P. V., Ross, D., and Gibson, N. W., NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mytomycin sensitivity, Cancer Res., 1995.
138. Rosvold, E. A., McGlynn, K. A., Lustbader, E. D., and Buetow, K. H., Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking, Pharmacogenetics, 5, 199, 1995.
139. Jim, C.-J., Miners, J. O., Burchell, B., and Mackenzie, P. I., The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP glucuronosyltransferases, Carcinogenesis, 14, 2637, 1993.
140. Moghrabi, N., Clarke, D. J., Burchell, B., and Boxer, M., Cosegregation of intragenic markers with a novel mutation that causes Crigler-Najjar type I: implication in carrier detection and prenatal diagnosis, Am. J. Hum. Genet., 53, 722, 1993.
141. Patel, M., Tang, B. K., and Kalow, W., (S)Oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7, Pharmacogenetics, 5, 43, 1995.
142. Bonicke, R. and Reif, W., Enzymatic inactivation of isonicotinic acid hydrazide in humans and animals, Arch. Exp. Pathol. Pharmakol. 220, 321, 1953.
143. Bonicke, R. and Lisboa, B. P., On the inherited basis of intraindividual constancy of isoniazid elimination in man (studies of monozygotic and dizygotic twins), Naturwissenschaften, 44, 314, 1957.
144. Weber, W. W. and Hein, D. W., N-acetylation pharmacogeneties, Pharmacol. Rev., 37, 25, 1985.
145. Hickman, D. and Sim, E., N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans, Biochem. Pharmacol., 42, 1007, 1991.
146. Blum, M., Grant, D. M., McBride, O. W., Heim, M., and Meyer, U. A., Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression, DNA Cell Biol., 9, 193, 1990.
147. Ohsako, S. and Deguchi, T., Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver, J. Biol. Chem., 265, 4630, 1990.
148. Ebisawa, T. and Deguchi, T., Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferase, Biochem. Biophys. Res. Commun., 177, 1252, 1991.
149. Bell, D. A., Taylor, J. A., Butler, M. A., Stephens, E. A., Wiest, J., Brubacker, L. H., Kadlubar, F. F., and Lucier, G. W., Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new acetylator allele common in African-Americans, Carcinogenesis, 14, 1689, 1993.
150. Abe, M., Deguchi, T., and Suzuki, T., The structure and characteristics of a fourth allele of polymorphic n-acetyltransferase gene found in the Japanese population, Biochem. Biophys. Res. Commun., 191, 811, 1993.
151. Vatsis, K. P., Weber, W. W., Bell, D. A., Dupret, J.-M., Evans, D. A. P., Grant, D. M., Hein, D. W., Lin, H. J., Meyer, U. A., Relling, M. V., et al., Nomenclature for N-acetyltransferases, Pharmacogenetics, 5, 1, 1995.
152. Rothman, N., Hayes, R. B., Bi, W., Caporaso, N., Broly, F., Woosley, R. L., Yin, S., Feng, P., You, X., and Meyer, U. A., Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males, Pharmacogenetics, 3, 250, 1993.
153. Cascorbi, I., Drakoulis, N., Brockmöller, J., Maurer, A., Sperling, K., and Roots, I., Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity, Am. J. Hum. Genet., 57, 581, 1995.
154. Cartwright, R. A., Epidemiological studies on N-acetylation and C-center ring oxidation in neoplasia, in Genetic Variability in Responses to Chemical Exposure, Omenn, G. S. and Gelboin, H. V., Eds., Cold Spring Harbor Laboratory, New York, 1984, 359.
155. Karakaya, A. E., Cok, I., Sardas, S., and Gogus, O. S., N-Acetyltransferase phenotype of patients with bladder cancer, Hum. Toxicol., 5, 333, 1989.
156. Hayes, R., Bi, W., Rothman, N., Broly, F., Caporaso, N., Feng, P., You, X., Yin, S., Woosley, R. L., and Meyer, U. A., N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers, Carcinogenesis, 14, 675, 1993.
157. Lang, N. P., Butler, M. A., Massengill, J. P., Lawson, M., Stotts, R. C., Hauer-Jensen, M., and Kadlubar, F. F., Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps, Cancer Epidemiol. Biomark. Prev., 3, 675, 1994.
158. Vatsis, K. P., Martell, K. J., and Weber, W. W., Diverse point mutations in the human gene for polymorphic N-acetyltransferase, Proc. Natl. Acad. Sci. U.S.A., 88, 6333, 1991.
159. Weber, W. W. and Vatsis, K. P., Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) or peripheral blood, Pharmacogenetics, 3, 209, 1993.
160. Bell, D. A., Badawi, A. F., Lang, N. P., Ilett, K. F., Kadlubar, F. F., and Hirvonen, A., Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue, Cancer Res., 55, 5226, 1995.
161. Badawi, A. F., Hirvonen, A., Bell, D. A., Lang, N. P., and Kadlubar, F. F., Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogenDNA adduct formation in the human urinary bladder, Cancer Res., 55, 5230, 1995.
162. Bell, D. A., Stephens, E. A., Castranio, T., Umbach, D. M., Watson, M., Deakin, M., Elder, J., Hendrickse, C., Duncan, H., and Strange, R. C., Polyadenylation polymorphism in the acetyltransferase I gene (NAT1) increases risk of colorectal cancer, Cancer Res., 55, 3537, 1995.
163. Hein, D. W., Doll, M. A., Rustan, T. D., Gray, K., Feng, Y., Ferguson, R. J., and Grant, D. M., Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases, Carcinogenesis, 14, 1633, 1993.
164. Vineis, P., Bartsch, H., Caporaso, N., Harrington, A. M., Kadlubar, F. F., Landi, M. T., Malaveille, C., Shields, P. G., Skipper, P., Talaska, G., et al., Genetically-based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens, Nature (London), 369, 154, 1994.
165. Daniel, V., Glutathione S-transferases: gene structure and regulation of expression, Crit. Rev. Biochem. Mol. Biol., 28, 173, 1993.
166. Mannervik, B. and Danielson, U. H., Glutathione transferases - structure and catalytic activity, CRC Crit. Rev. Biochem., 23, 281, 1988.
167. Awasthi, Y. C., Sharma, R., and Singhal, S. S., Human glutathione S-transferases, Int. J. Biochem., 26, 295, 1994.
168. Zhong, S., Wyllie, A. H., Barnes, D., Wolf, C. R., and Spurr, N. K., Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer, Carcinogenesis, 14, 1821, 1993.
169. Fryer, A. A., Zhao, L., Alldersea, J., Pearson, W. R., and Strange, R. C., Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A,B and GSTM1 null polymorphisms at the glutathione S-transferase, GSTM1 locus, Biochem. J., 295, 313, 1993.
170. Bell, D. A., Taylor, J. A., Paulson, D. F., Robertson, C. N., Mohler, J. L., and Lucier, G. W., Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer, J. Natl. Cancer Inst., 85, 1159, 1993.
171. Nakajima, T., Elovaara, E., Anttila, S., Hirvonen, A., Camus, A. M., Hayes, J. D., Ketterer, B., and Vainio, H., Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer, Carcinogenesis, 16, 707, 1995.
172. Fryer, A. A., Zhao, L., Alldersea, J., Boggild, M. D., Perrett, C. W., Clayton, R. N., Jones, P. W., and Strange, R. C., The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas, Carcinogenesis, 14, 563, 1993.
173. Anttila, S., Hirvonen, A., Husgafvel-Pursiainen, K., Karjalainen, A., Nurminen, T., and Vainio, H., Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer, Carcinogenesis, 15, 1133, 1994.
174. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S., and Vainio, H., The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung, Carcinogenesis, 14, 1479, 1993.
175. Ketterer, B., Harris, J. M., Talaska, G., Meyer, D. J., Pemble, S. E., Taylor, J. B., Lang, N. P., and Kadlubar, F. F., The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer, Env. Health Perspect., 98, 87, 1992.
176. London, S. J., Daly, A. K., Cooper, J., Navidi, W. C., Carpenter, C. L., and Idle, J. R., Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles county, California, J. Natl. Cancer Inst., 87, 1246, 1995.
177. Trizna, Z., Clayman, G., Spitz, M. R., Briggs, K. L., and Goepfert, H., Glutathione S-transferase genotypes as risk factors for head and neck cancer, Am. J. Surgery, 170, 499, 1995.
178. Heagerty, A. H. M., Fitzgerald, D., Smith, A., Bowers, B., Jones, P., Fryer, A. A., Zhao, L., Alldersea, J., and Strange, R. C., Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours, Lancet, 343, 266, 1994.
179. Lafuente, A., Molina, R., Palou, J., Castel, T., Moral, A., Trias, M., and the MMM Group, Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma, Br. J. Cancer, 72, 324, 1995.
180. Lin, H. J., Han, C.-Y., Bernstein, D. A., Hsiao, W., Lin, B. K., and Hardy, S., Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility, Carcinogenesis, 15, 1077, 1994.
181. Nakachi, K., Imai, K., Hayashi, S.-I., and Kawajiri, K., Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population, Cancer Res., 53, 2994, 1993.
182. Kawajiri, K., Watanabe, J., Eguchi, H., and Hayashi, S.-I., Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility, Pharmacogenetics, 5, S70, 1995.
183. Kihara, M., Kihara, M., and Noda, K., Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure, Carcinogenesis, 15, 415, 1994.
184. Kihara, M., Noda, K., and Kihara, M., Distribution of GSTM1 null genotype in relation to gender, age and smoking status in Japanese lung cancer patients, Pharmacogenetics, 5, S74, 1995.
185. Hirvonen, A., Nylund, L., Kociba, P., Husgafvel-Pursiainen, K., and Vainio, H., Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers, Carcinogenesis, 15, 813, 1994.
186. Anttila, S., Luostarinen, L., Hirvonen, A., Elovaara, E., Karjalainen, A., Nurminen, T., Hayes, J. D., Vainio, H., and Ketterer, B., Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure, Cancer Res., 55, 3305, 1995.
187. Pemble, S., Schroeder, K. R., Spencer, S. R., Meyer, D. J., Hallier, E., Bolt, H. M., Ketterer, B., and Taylor, J. B., Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterisation of a genetic polymorphism, Biochem. J., 300, 271, 1994.
188. Elexpuru-Camiruaga, J., Buxton, N., Kandula, V., Dias, P., Campbell, D., McIntosh, J., Broome, J., Jones, P., Inskip, A., Alldersea, J., et al., Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci, Cancer Res., 55, 4237, 1995.
189. Warwick, A., Sarhanis, P., Redman, C., Pemble, S., Taylor, J. B., Ketterer, B., Jones, P., Alldersea, J., Gilford, J., Yengi, L., et al., Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: interactions with GSTM1, CYP2D6 and smoking, Carcinogenesis, 15, 2841, 1994.
190. Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F., Human P450PA (P-450-1A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic amines, Proc. Natl. Acad. Sci. U.S.A., 86, 7696, 1989.
191. Crespi, C. L., Penman, B. W., Gelboin, H. V., and Gonzalez, F. J., A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple cytochrome P450s including the polymorphic cytochrome P4502D6, Carcinogenesis, 12, 1197, 1991.
192. Ikeya, K., Jaiswal, A. K., Owens, R. A., Jones, J. E., Nebert, D. W., and Kimura, S., Human CYP1A2. Sequence, gene structure, comparison with the mouse and rat orthologous gene, and genetic differences in liver 1A2 mRNA concentrations, Mol. Endocrinol., 3, 1399, 1989.
193. Yamazaki, H., Mimura, M., Oda, Y., Inui, Y., Shiraga, T., Iwasaki, K., Guengerich, F. P., and Shimada, T., Roles of different forms of cytochrome P450 in the activation of the promutagen 6-aminochrysene to genotoxic metabolites in human liver microsomes, Carcinogenesis, 14, 1271, 1993.
194. Kadlubar, F. F., Butler, M. A., Kaderlik, K. R., Chou, H.-C., and Lang, N. P., Polymorphisms for aromatic amine metabolism in humans: relevance for human Carcinogenesis, Environ. Health Perspect., 98, 69, 1992.
195. Shimada, T., Yun, C.-H., Hiroshi, Y., Gautier, J.-C., Beaune, P. H., and Guengerich, F. P., Characterization of human lung microsomal cytochrome P4501A1 and its role in the oxidation of chemical carcinogens, Mol. Pharmacol., 41, 856, 1992.
196. Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., and Kadlubar, F. F., Determination of CYP1A2 and acetyltransferase phenotype in human populations by analysis of caffeine urinary metabolites, Pharmacogenetics, 2, 116, 1992.
197. Kapitulnik, J., Poppers, P. J., and Conney, A. H., Comparative metabolism of benzo(a)pyrene and drugs in human liver, Clin. Pharmacol. Ther., 21, 166, 1977.
198. Miles, J. S., McLaren, A. W., Forrester, L. M., Glancey, M. J., Lang, M. A., and Wolf, C. R., Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity, Biochem. J., 267, 365, 1990.
199. Yamano, S., Tatsuno, J., and Gonzalez, F. J., The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes, Biochemistry, 29, 1322, 1990.
200. Maurice, M., Emiliani, S., Dalet-Beluche, I., Derancourt, J., and Lange, R., Isolation and characterization of a cytochrome P-450 of the IIA subfamily from human liver microsomes, Eur. J. Biochem., 200, 365, 1991.
201. Fernandez-Salguero, P., Hoffman, S. M. G., Cholerton, S., Mohrenweiser, H., Raunio, H., Rautio, A., Pelkonen, O., Huang, J. D., Evans, W. E., Idle, J. R., et al., A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles, Am. J. Hum. Genet., 57, 651, 1995.
202. Ding, X. and Coon, M. J., Purification and characterization of two unique forms of cytochrome P450 from rabbit nasal microsomes, Biochemistry, 27, 8330, 1988.
203. Fernandez-Salguero, P. and Gonzalez, F. J., The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis, Pharmacogenetics, 5, S123, 1995.
204. Bale, A. E., Mitchell, A. L., Gonzalez, F. J., and McBride, O. W., Localization of CYP2F1 by multipoint linkage analysis and pulse-field gel electrophoresis, Genomics, 10, 284, 1991.
205. Ged, C., Umbenhauer, D. R., Bellew, T. M., Bork, R. W., Srivastava, P. K., Shinriki, N., Lloyd, R. S., and Guengerich, F. P., Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase, Biochemistry, 27, 6929, 1988.
206. Inoue, K., Inazawa, J., Suzuki, Y., Shimada, T., Yamazaki, H., Guengerich, F. P., and Abe, T., Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1, Jpn. J. Hum. Genet., 39, 337, 1994.
207. Kupfer, A. and Preisig, R., Pharmacogenetics of mephenytoin: new drug hydroxylation polymorphism in man, Eur. J. Clin. Pharmacol., 26, 753, 1984.
208. Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., and Ghanayem, B. I., Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans, Biochemistry, 33, 1743, 1994.
209. de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., and Goldstein, J. A., The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J. Biol. Chem., 269, 15419, 1994.
210. Wrighton, S. A., Stevens, J. C., Becker, G. W., and VandenBranden, M., Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation, Arch. Biochem. Biophys., 306, 240, 1993.
211. Goldstein, J. A. and de Morais, S.M., Biochemistry and molecular biology of the human CYP2C subfamily, Pharmacogenetics, 4, 285, 1994.
212. Brockmoller, J., Rost, K. L., Gross, D., Schenkel, A., and Roots, I., Phenotyping of CYP2C19 with enantio-specific HPLC-quantificationof R- and S-mephenytoin and comparison with the intron4/exon5 G→A-splice site mutation, Pharmacogenetics, 5, 80, 1995.
213. Adedoyin, A., Prakash, C., O'Shea, D., Blair, I. A., and Wilkinson, G. R., Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects, Pharmacogenetics, 4, 27, 1994.
214. Yasumori, T., Li, Q. H., Yamazoe, Y., Ueda, M., Tsuzuki, T., and Kato, R., Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation, Pharmacogenetics, 4, 323, 1994.
215. Yasumori, T., Nagata, K., Yang, S. K., Chen, L. S., Murayama, N., Yamazoe, Y., and Kato, R., Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner, Pharmacogenetics, 3, 291, 1993.
216. Cresteil, T., Monsarrat, B., Alvinerie, P., Treluyer, J. M., Vieira, I., and Wright, M., Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation, Cancer Res., 54, 386, 1994.
217. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J., and Harris, J. W., Selective biotransformation of taxol to 6α-hydrotaxol by human cytochrome P450 2C8, Cancer Res., 54, 5543, 1994.
218. Watkins, P. B., Noninvasive tests of CYP3A enzymes, Pharmacogenetics, 4, 171, 1994.
219. Breimer, D. D., Schellens, J. M. H., and Soons, P. A., Nifepidine: variability in its kinetics and metabolism in man, Pharmacol. Ther., 44, 445, 1989.
220. Fleming, C. M., Branch, R. A., Wilkinson, G. R., and Guengerich, F. P., Human liver microsomal N-hydroxylation of dapsone by cytochrome P4503A4, Mol. Pharmacol., 41, 975, 1992.
221. Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A., and Guzelian, P. S., Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P450, J. Clin. Invest., 83, 688, 1989.
222. Kolars, J. C., Lown, K. S., Schmiedlin-Ren, P., Ghosh, M., Fang, C., Wrighton, S. A., Merion, R. M., and Watkins, P. B., CYP3A gene expression in human gut epithelium, Pharmacogenetics, 4, 247, 1994.
223. Daly, A. K., Salh, B. S., Bilton, D., Allen, J., Knight, A. D., Webb, A. K., Braganza, J. M., and Idle, J. R., Deficient nifepidine oxidation: a rare inherited trait associated with cystic fibrosis kindreds, Pharmacogenetics, 2, 19, 1992.
224. Furlong, C. E., Costa, L. G., Hassett, C., Richter, R. J., Sundstrom, J. A., Adler, D. A., Disteche, C. M., Omiecinski, C. J., Chapline, C., and Crabb, J. W., Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification, Chem. Biol. Interact., 87, 35, 1993.
225. Tsui, L. C., Buchwald, M., Barker, D., Braman, J. C., Knowlton, R., Schumm, J. W., Eiberg, H., Mohr, J., Kennedy, D., and Plavsic, N., Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker, Science, 230, 1054, 1985.
226. Knowlton, R. G., Cohen-Haguenauer, O., Van Cong, N., Frezal, J., Brown, V. A., Barker, D., Braman, J. C., Schumm, J. W., Tsui, L. C., and Buchwald, M., A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7, Nature, (London), 318, 380, 1985.
227. Adkins, S., Gan, K. N., Mody, M., and La Du, B. N., Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes, Am. J. Hum. Genet., 52, 598, 1993.
228. Karakaya, A., Suzen, S., Sardas, S., Karakaya, A. E., and Vural, N., Analysis of the serum paraoxonase/arylesterase polymorphism in a Turkish population, Pharmacogenetics, 1, 58, 1991.
229. Roy, A. C., Saha, N., Tay, J. S., and Ratnam, S. S., Serum paraoxonase in three populations of Southeast Asia, Hum. Hered., 41, 265, 1991.
230. Clavel, J. and Hemon, D., Fundamentals of case-control studies, Pharmacogenetics, 3, 160, 1993.
231. Lander, E. S. and Schork, N. J., Genetic dissection of complex traits, Science, 265, 2037, 1994.
232. Lifton, R. P. and Jeunemaitre, X., Finding genes that cause human hypertension, J. Hypertens., 11, 231, 1993.
233. Jeunemaitre, X., Rigat, B., Charru, A., Houot, A. M., Soubrier, F., and Corvol, P., Sib pair linkage analysis of renin gene haplotypes in human essential hypertension, Hum. Genet., 88, 301, 1992.
234. Jeunemaitre, X., Soubrier, F., Kotelevtsev, Y. V., Lifton, R. P., Williams, C. S., Charru, A., Hunt, S. C., Hopkins, P. N., Williams, R. R., and Lalouel, J. M., Molecular basis of human hypertension: role of angiotensinogen, Cell, 71, 169, 1992.
235. Pritchard, L. E., Kawaguchi, Y., Reed, P. W., Copeman, J. B., Davies, J. L., Barnett, A. H., Bain, S. C., and Todd, J. A., Analysis of the CD3 gene region and type 1 diabetes: application of fluorescence-based technology to linkage disequilibrium mapping, Hum. Mol. Genet., 4, 197, 1995.
236. Davies, J. L., Kawaguchi, Y., Bennett, S. T., Copeman, J. B., Cordell, H. J., Pritchard, L. E., Reed, P. W., Gough, S. C., Jenkins, S. C., and Palmer, S. M., A genome-wide search for human type 1 diabetes susceptibility genes, Nature, (London), 371, 130, 1994.
237. Reed, P. W., Davies, J. L., Copeman, J. B., Bennett, S. T., Palmer, S. M., Pritchard, L. E., Gough, S. C., Kawaguchi, Y., Cordell, H. J., and Balfour, K. M., Chromosome-specific microsatellite sets for fluorescence-based, semi-automated genome mapping, Nature Genet., 7, 390, 1994.
238. Williams, R. J., Biochemical Individuality, John Wiley & Sons, New York, 1956.
239. Nelson, D. B., Nerbert, D. W., et al., Pharmacogenetics, 6, 1, 1996.
240. Micka, et al., Pharmacogenetics, in press.
241. Daly, A. K. et al., Pharmacogenetics, 6, 193, 1996.
242. Meyer, U. A., personal communication.
243. Shertzer, H. G. and Nerbert, D. W., unpublished data.